Interesting...
https://www.fiercebiotech.com/biotech/astrazeneca-pays-sobi-95m-for-priority-review-voucher
For Sobi, the deal provides a near-instant partial return on the $518 million it paid to acquire FNγ inhibitor emapalumab and associated assets from NovImmune in June. Sobi licensed the global rights to emapalumab in 2018, after NovImmune filed for approval, but that deal left it without the priority review voucher the FDA awarded upon authorizing the drug later in the year. Sobi then returned to NovImmune to acquire the priority review voucher and other assets.
- Forums
- ASX - By Stock
- RAC
- AstraZeneca pays Sobi $95M for priority review voucher
AstraZeneca pays Sobi $95M for priority review voucher
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
0.080(5.00%) |
Mkt cap ! $272.6M |
Open | High | Low | Value | Volume |
$1.63 | $1.69 | $1.52 | $127.3K | 79.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 6639 | $1.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 418 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 6639 | 1.635 |
1 | 19532 | 1.630 |
1 | 140 | 1.625 |
1 | 10000 | 1.620 |
1 | 25000 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.685 | 418 | 2 |
1.700 | 2484 | 1 |
1.735 | 6763 | 2 |
1.740 | 360 | 1 |
1.750 | 26309 | 3 |
Last trade - 12.37pm 28/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
SPONSORED BY The Market Online